SHP 656

Drug Profile

SHP 656

Alternative Names: BAX 826; Bax-826; Polysialylated rFVIII; PSA-FVIII - Shire/Xenetic Biosciences; PSA-rFVIII; SHP-826

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator Baxter International; Xenetic Biosciences
  • Developer Shire; Xenetic Biosciences
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haemophilia A

Most Recent Events

  • 03 Apr 2017 Xenetic Biosciences plans a phase III trial for Haemophilia A
  • 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
  • 21 Nov 2016 Preclinical data presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top